Amyloidosis is officially classified as a rare disease, but growing evidence suggests it is far more common than the diagnosis rate implies. Tens of thousands of cases worldwide go undetected each year, with diagnostic delays often stretching well past a year. The gap between how rare amyloidosis appears in medical records and how often it actually occurs in human tissue is one of the more striking disconnects in modern medicine.
What the Numbers Actually Show
The statistics depend heavily on which type of amyloidosis you’re looking at, and on whether you count only confirmed diagnoses or include cases found incidentally at autopsy or through screening studies. For AL amyloidosis, the most commonly diagnosed systemic form, estimated global incidence sits at roughly 10 cases per million people per year, with about 74,000 cases diagnosed worldwide over a twenty-year window ending in 2018.1PubMed Central. Global epidemiology of amyloid light-chain amyloidosis More recent U.S. data using electronic health records puts the AL amyloidosis incidence higher, at about 17 per million adults in 2021, with prevalence around 69 per million.2Scientific Reports. Incidence and prevalence of light chain amyloidosis in the United States in 2019–2021 using Optum EHR data Those numbers sound small until you realize they translate to thousands of new cases per year in the U.S. alone.
Transthyretin cardiac amyloidosis (ATTR-CM), the type that primarily affects the heart, tells an even more striking story. Among U.S. Medicare beneficiaries aged 65 and older, the incidence reached about 44 per 100,000 person-years in 2021, with prevalence climbing to roughly 96 per 100,000 by 2022.3PubMed Central. Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States That rate has been rising steeply year over year, not because more people are developing the disease, but because awareness and diagnostic tools have improved. Korean data shows a similar upward trajectory: the annual prevalence of cardiac amyloidosis jumped more than sixfold between 2009 and 2020.4PubMed Central. Temporal trends in the prevalence, incidence, and mortality of cardiac amyloidosis in Korea over 12 years The disease hasn’t changed. The ability to find it has.
The Main Types of Amyloidosis
Amyloidosis isn’t a single disease. It’s a family of conditions in which abnormal proteins fold into insoluble fibers and build up in organs, gradually damaging tissue and impairing function.5PubMed. Systemic Amyloidosis: a Contemporary Overview The type depends on which protein is misbehaving, and that distinction matters enormously for treatment, prognosis, and who’s at risk.
AL amyloidosis (light chain) occurs when abnormal plasma cells in the bone marrow produce excess immunoglobulin light chains that misfold and deposit in organs.6PubMed Central. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication It can affect the heart, kidneys, liver, nerves, and soft tissues. Because it’s driven by a clonal blood-cell disorder, treatment overlaps with blood cancer therapies including chemotherapy and stem cell transplant. This is the type most often diagnosed by hematologists.
Wild-type ATTR amyloidosis (ATTRwt) involves normal, non-mutated transthyretin protein that becomes unstable with aging and deposits primarily in the heart. It overwhelmingly affects older men. In one prospective study of heart failure patients with preserved or mildly reduced pumping function, about 5% turned out to have wild-type ATTR, with the rate reaching about 13% among those who also had thickened heart walls.7European Journal of Heart Failure. Prevalence of Wild-Type Transthyretin Amyloidosis in a Prospective Heart Failure Cohort with Preserved and Mildly Reduced Ejection Fraction That finding alone suggests a huge reservoir of undiagnosed disease hiding in cardiology clinics.
Hereditary ATTR amyloidosis (ATTRv) is caused by mutations in the transthyretin gene. Global prevalence is estimated at roughly 10,000 people, though the true number may be several times higher. Clusters exist in Portugal, Sweden, Brazil, and Japan, where prevalence in certain subregions can reach more than 1,600 per million.8PubMed Central. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy In the United States, the most common mutation (Val122Ile) originated in West Africa and is carried by roughly 3–4% of African Americans, though only a fraction develop symptomatic disease.9PubMed Central. ATTR Epidemiology, Genetics, and Prognostic Factors Among patients referred for genetic testing, that variant accounted for 84% of all pathogenic findings.10PubMed Central. Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program
AA amyloidosis develops secondary to chronic inflammatory diseases like rheumatoid arthritis and ankylosing spondylitis. Sustained inflammation drives high levels of serum amyloid A protein, which can misfold and deposit in the kidneys and other organs.11PubMed. Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments The good news is that modern biologic therapies have dramatically cut its prevalence. In rheumatoid arthritis, rates dropped from roughly 17–25% before 2010 to under 1% afterward.12PubMed. AA amyloidosis in inflammatory joint diseases: A systematic review Better control of the underlying inflammation simply removes the fuel.
Dialysis-related amyloidosis is caused by beta-2 microglobulin building up in patients on long-term hemodialysis. The protein deposits in joints and tendons, and less commonly in the heart.13PubMed Central. Beta-2 Microglobulin Amyloidosis: Past, Present, and Future In older autopsy studies of dialysis patients, amyloid deposits were present in nearly half after a median of about four years on hemodialysis, far exceeding the rate found through clinical symptoms alone.14PubMed. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study Modern high-flow dialysis membranes have made new cardiac cases uncommon, though joint involvement still occurs with prolonged dialysis.15PubMed. The pathology and changing epidemiology of dialysis-related cardiac beta-2 microglobulin amyloidosis
Why So Many Cases Go Undiagnosed
Amyloidosis is a disease that hides behind common symptoms. Fatigue, shortness of breath, swollen ankles, numbness in the hands, unexplained weight loss: these are complaints that send people to cardiologists, nephrologists, or general practitioners, none of whom may be thinking about amyloid. A patient survey of people eventually diagnosed with AL amyloidosis found that 59% reported a meaningful diagnostic delay, with 35% waiting more than a year for their diagnosis. Half of those who experienced a delay attributed it to a lack of provider awareness.16PubMed. Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey
Claims data paints an even more granular picture. Before an AL amyloidosis diagnosis, patients typically see multiple cardiologists and nephrologists. Among those with cardiac involvement who experienced a delayed diagnosis, the average time from first cardiovascular symptom to confirmed diagnosis was nearly 600 days. Even after finally seeing a hematologist (the specialist most likely to make the diagnosis), another 100 days passed before confirmation. In contrast, patients who were diagnosed promptly received their diagnosis about 91 days after the first cardiac symptom.17BMJ Open. Diagnostic pathways, cardiac manifestations and outcomes in light chain amyloidosis: analysis of a US claims database
The ATTR-CM story is similar. In the Medicare population, the median gap between a heart failure diagnosis and an ATTR-CM diagnosis was about 494 days. For patients who had been placed on a loop diuretic (a standard heart failure medication) before their amyloidosis was recognized, the median lag was over 840 days.18JAMA Cardiology. Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population These are people being treated for heart failure for two years or more without anyone identifying the cause.
Carpal Tunnel Syndrome as an Early Warning
One of the most underappreciated clues to amyloidosis shows up in hand surgeons’ offices years before cardiac symptoms appear. Carpal tunnel syndrome caused by amyloid deposits in the wrist tendons is a well-documented early sign of systemic disease. In a study of patients undergoing carpal tunnel release surgery, amyloid was found in the tendon tissue of about 10% of men over 50 and women over 60, and every positive case had bilateral symptoms.19PubMed. Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis Patients with cardiac amyloidosis classically present with heart disease several years after carpal tunnel surgery. That window represents a missed opportunity: the amyloid was already building up in the wrists long before it caused heart failure, and nobody looked for it.
Nerve ultrasound research has found that even pre-symptomatic carriers of hereditary ATTR mutations show subtle structural changes in peripheral nerves, which could eventually serve as a way to identify people heading toward disease before symptoms begin.20PubMed Central. Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers
Hiding Alongside Aortic Stenosis
Older adults with aortic stenosis, a common narrowing of the heart’s aortic valve, represent another population where amyloidosis often goes unnoticed. The two conditions share overlapping symptoms and often coexist. Screening studies suggest that among patients over 65 with aortic stenosis, somewhere between 4% and 16% also have transthyretin cardiac amyloidosis.21PubMed Central. Cardiac amyloidosis and aortic stenosis: a state-of-the-art review In a multicenter study of patients being evaluated for transcatheter aortic valve replacement, nearly 12% had positive bone-tracer scans consistent with ATTR amyloid deposits in the heart.22PubMed Central. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis Finding amyloidosis in these patients matters because it changes both prognosis and treatment decisions. A valve replacement alone won’t address the amyloid steadily infiltrating the heart muscle.
How Diagnosis Has Improved
One reason cases went undetected for so long is that diagnosis historically required tissue biopsy with Congo red staining, an older laboratory technique that can miss early deposits and is prone to errors in typing. Mass spectrometry–based proteomics has transformed this. The technique can identify the specific amyloid protein in tissue samples with high accuracy and can even detect amyloid before the traditional Congo red stain turns positive.23PubMed Central. Laser microdissection and mass spectrometry–based proteomics aids the diagnosis and typing of renal amyloidosis When one center introduced proteomic typing, they found that the referring clinician’s initial subtype classification was wrong about a quarter of the time.24PubMed Central. Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry Mistyping matters enormously because AL and ATTR amyloidosis require completely different treatments.
For ATTR cardiac amyloidosis specifically, nuclear bone-tracer imaging (commonly called a PYP scan in the U.S.) has been a game-changer. The scan picks up transthyretin amyloid in the heart with high sensitivity and specificity, often eliminating the need for an invasive heart biopsy.25PubMed Central. The use of PYP scan for evaluation of ATTR cardiac amyloidosis at a tertiary medical centre Using a heart-to-chest uptake ratio threshold of 1.4 or higher, one validation study found 99% specificity and 93% sensitivity for ATTR cardiac amyloidosis.26PubMed Central. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc(99m) pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis The availability of a noninvasive, highly accurate test has been a major driver behind the rising diagnosis rates discussed earlier.
Artificial intelligence is also entering the picture. AI models trained on standard electrocardiograms and echocardiograms can flag patients who may have cardiac amyloidosis with reasonably high accuracy, achieving area-under-the-curve values of 0.85–0.91 for ECG-based detection and 0.89–1.00 for echocardiography-based detection across multiple academic centers.27Nature Communications. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms When the ECG model is used as a pre-screen before the echocardiography model, the positive predictive value jumps substantially, making the two-step approach a practical screening strategy. Similarly, natural language processing algorithms scanning electronic health records for clusters of red-flag symptoms in hereditary ATTR have demonstrated a nearly 49% increase in appropriate genetic testing referrals.28PubMed. Validation of an Artificial Intelligence driven framework to automatically detect red flag symptoms in screening for rare diseases in electronic health records These tools don’t replace specialists, but they can alert clinicians to consider amyloidosis in patients who would otherwise slip through.
Who Gets Amyloidosis
Amyloidosis doesn’t affect everyone equally. Wild-type ATTR is overwhelmingly a disease of older men. Hereditary ATTR varies by mutation and geography: the Val30Met mutation clusters in Portugal, Sweden, Japan, and parts of Brazil, while the Val122Ile variant is concentrated in people of West African descent. In the U.S., the Val122Ile carrier rate of 3–4% among African Americans makes hereditary ATTR amyloidosis one of the most common single-gene cardiac diseases in that population, though many carriers never develop clinically apparent disease.9PubMed Central. ATTR Epidemiology, Genetics, and Prognostic Factors
Disparities go beyond biology. A large U.S. study of AL amyloidosis found that non-Hispanic Black patients had higher-risk sociodemographic profiles and were roughly a quarter more likely to die when adjusting only for age and sex. However, that increased risk disappeared after accounting for disease severity and treatment received, suggesting the gap is driven by later diagnosis and unequal access to care rather than inherent biological differences.29Blood Cancer Journal. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities Hispanic patients in the same study were 30% less likely to receive stem cell transplant compared to white patients, partly due to socioeconomic factors. Minority patients also presented an average of four to six years younger.
Survival Has Improved, but Early Diagnosis Remains the Bottleneck
For AL amyloidosis, the trajectory is encouraging even if the baseline is grim. Between 1966 and 1987, only about 5% of patients survived ten years. By 2004–2008, the ten-year survival rate had climbed to 25%.30PubMed Central. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern That improvement tracks with the introduction of effective chemotherapy regimens and autologous stem cell transplant.
For ATTR cardiac amyloidosis, the stabilizer drug tafamidis has reshaped the outlook. In a large European registry, the three-year survival rate for treated patients was 57% compared with 40% for untreated patients. Even among those over 85, treatment was associated with a 58% three-year survival rate.31PubMed. Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry Liver transplantation, the original disease-modifying strategy for hereditary ATTR, has been performed in over 2,000 patients since 1990 and demonstrably extends life by removing the organ that produces the mutant protein.32PubMed. Liver transplantation and transthyretin amyloidosis Newer gene-silencing therapies and protein stabilizers now offer alternatives that do not require major surgery.33PubMed Central. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs
The catch is that these treatments work best when started early, before irreversible organ damage accumulates. That’s what makes the diagnostic delays described earlier so consequential. A patient diagnosed 600 days after their first cardiac symptom has spent nearly two years losing ground that could have been held.
The Financial and Personal Cost
Beyond the clinical challenges, amyloidosis carries a steep financial and personal burden. In a Taiwanese claims analysis, patients with AL amyloidosis incurred annual healthcare costs roughly six times higher than matched comparators in the first year after diagnosis, with over half of the three-year cumulative cost concentrated in that first year.34PubMed Central. Healthcare resource utilisation and costs associated with AL amyloidosis: a retrospective matched cohort study In the U.S., 55% of ATTR amyloidosis patients surveyed reported financial toxicity, with younger patients, non-white patients, and those with household incomes under $100,000 disproportionately affected. Many reported delaying treatment or borrowing money to afford it.35PubMed. Factors associated with financial toxicity in patients with transthyretin amyloidosis
Caregivers bear significant strain as well. In a survey-based study, caregivers of ATTR amyloidosis patients reported spending an average of about 46 hours per week providing care, alongside notable impacts on their own mental health and ability to work.36PubMed Central. Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers That’s essentially a second full-time job, often on top of the caregiver’s actual employment. The financial distress reported by amyloidosis patients is comparable to what cancer patients experience, which is striking given how much less public attention amyloidosis receives.